RxDoctor Payments Data

Matthew Schmidt, MD

Ophthalmology · Palos Heights, ILNPI 1194860395

Payments from drug & device makers

$4,200in general payments, 2019–2025

Across 170 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$882
  • Sight Sciences, Inc.$622
  • Alcon$560
  • Sun Pharmaceutical Industries Inc.$312
  • Harrow Eye, LLC$233
  • Novartis$209
  • plus $1K from 14 others

What the payments were for

  • Speaking & faculty fees$321%
  • Food & beverage$4,04896%
  • Gifts$130%
  • Entertainment$1083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,200 in reported general payments places this provider in the 75th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$662,799
Medicare patients
2,243
Services billed
6,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost541$217,417
RestasisCyclosporine115$110,086
CombiganBrimonidine Tartrate/Timolol90$36,529
MieboPerfluorohexyloctane/Pf44$33,039
RhopressaNetarsudil Mesylate64$29,571
XiidraLifitegrast23$28,813
Alphagan PBrimonidine Tartrate82$24,231
VyzultaLatanoprostene Bunod42$15,844
Bromfenac Sodium116$12,604
ZioptanTafluprost/Pf25$11,619
Travoprost57$11,328
Prednisolone Acetate355$10,272
ProlensaBromfenac Sodium28$9,646
Cosopt PfDorzolamide/Timolol/Pf21$8,268
RocklatanNetarsudil Mesylat/Latanoprost11$8,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$882$388,262828 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$115$77,696109 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$171$37,70575 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$193$9,64628 claims
AlconAzopt$560$7,76812 claims
NovartisTravatan Z$209$5,93112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →